Home About Us Categories Latest Reports News Room Contact us

NA Taxane Market - Industry Trends and Forecast to 2029

Report Code: 81645

Industry: Pharma & Healthcare

Published On: 2022/07/22

Pages: 202

Publisher : Data Bridge Market Research

North America taxane market is projected to register a substantial CAGR of 7.7% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.
Market Segmentation:
North America Taxane Market, By Type (Paclitaxel, Docetaxel, Cabazitaxel), Drug Type (Generics, Branded), Formulation (Liposomes, Nanoparticles, Polymeric Micelles, Others), Age Group (Adults, Geriatric), Application (Breast Cancer, Non-Small Lung Cancer, Pancreatic Cancer, Ovarian Cancer, Prostate Cancer, Others), End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Others) Distribution Channel (Retail Sales, Direct Tender), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2029

Some of the major factors contributing to the growth of the North America taxane market are:

• The rise in incidence of cancer
• The funding by the government and investment in research and development
Market Segmentation:
North America taxane market is categorized into seven notable segment which is type, drug type, formulation, age group, application, end user and distribution channel.

• On the basis of type, the North America taxane market is segmented into paclitaxel, docetaxel and cabazitaxel.
• On the basis of application, the North America taxane market is segmented into ovarian cancer, breast cancer, prostate cancer, non-small cell lung cancer and other
• On the basis of drug type, the North America taxane market is segmented into branded and generics
• On the basis of formulation, the North America taxane market is segmented into liposomes, nanoparticles, polymeric micelles and others
• On the basis of age group, the North America taxane market is segmented into adults and geriatric
• On the basis of end user, the North America taxane market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others
• On the basis of distribution channel, the North America taxane market is segmented into direct tender, retail sales


Market Players:

The key market players for North America taxane market are listed below:

• Panacea Biotec
• RPG Life Sciences Limited.
• Aureate Healthcare
• Cipla Inc.
• Hetero Healthcare Limited.
• AqVida GmbH
• Ingenus Pharmaceuticals, LLC

Market Definition:

The taxanes or taxoids are a closely related group of antineoplastic agents that have a unique mechanism of action as inhibitors of mitosis and which are widely used in the therapy of ovarian, breast, lung, esophageal, prostate, bladder and head and neck cancers. Three taxanes are in clinical use, paclitaxel (Taxol: 1992), docetaxel (Taxotere: 1996) and cabazitaxel (Jevtana: 2010). Taxanes are anticancer drugs that interfere with microtubule function, causing changes in mitosis and cellular death. Paclitaxel (Taxol) was first isolated from a yew tree, a small evergreen coniferous tree with a slow growth rate. As paclitaxel was initially scarce, docetaxel (Taxotere), a semisynthetic analogue of paclitaxel derived from the needles of the European yew tree Taxus baccata, was created. Docetaxel differs from paclitaxel in two chemical locations, making it more water soluble. Lung cancer, prostate cancer, squamous cell carcinoma of the head and neck, breast cancer, Kaposi's sarcoma, gastric cancer, bladder cancer, esophageal cancer and other carcinomas are all commonly treated with paclitaxel and docetaxel. Cabazitaxel is also a semisynthetic analogue of natural taxoids and was developed for its lack of affinity for P-glycoprotein, a common mediator of docetaxel resistance.
Market Segmentation:
The North America taxane market is categorized into seven notable segments which are based type, drug type, formulation, age group, application, end user and distribution channel.

• On the basis of type, the North America taxane market is segmented into paclitaxel, docetaxel and cabazitaxel
• On the basis of drug type, the North America taxane market is segmented into branded and generics
• On the basis of formulation, the North America taxane market is segmented into liposomes, nanoparticles, polymeric micelles, others
• On the basis of age group, the North America taxane market is segmented into adults and geriatric
• On the basis of application, the North America taxane market is segmented into ovarian cancer, breast cancer, prostate cancer, pancreatic cancer, non-small cell lung cancer and other
• On the basis of end user, the North America taxane market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others
• On the basis of distribution channel, the North America taxane market is segmented into direct tender, retail sales

TABLE OF CONTENTS
1 INTRODUCTION 38
1.1 OBJECTIVES OF THE STUDY 38
1.2 MARKET DEFINITION 38
1.3 OVERVIEW OF NORTH AMERICA TAXANE MARKET 38
1.4 CURRENCY AND PRICING 40
1.5 LIMITATIONS 40
1.6 MARKETS COVERED 41
2 MARKET SEGMENTATION 45
2.1 MARKETS COVERED 45
2.2 GEOGRAPHICAL SCOPE 46
2.3 YEARS CONSIDERED FOR THE STUDY 47
2.4 DBMR TRIPOD DATA VALIDATION MODEL 48
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 51
2.6 MULTIVARIATE MODELLING 52
2.7 MARKET APPLICATION COVERAGE GRID 52
2.8 TYPE LIFELINE CURVE 53
2.9 DBMR MARKET POSITION GRID 54
2.10 VENDOR SHARE ANALYSIS 56
2.11 SECONDARY SOURCES 57
2.12 ASSUMPTIONS 57
3 EXECUTIVE SUMMARY 58
4 PREMIUM INSIGHT 62
4.1 PESTEL_ANALYSIS 63
4.2 PORTER'S FIVE FORCES MODEL 64
5 EPIDEMIOLOGY 65
6 INDUSTRIAL INSIGHTS 66
6.1 CONCLUSION 67
7 NORTH AMERICA TAXANE MARKET: REGULATIONS 68

8 MARKET OVERVIEW 73
8.1 DRIVERS 75
8.1.1 THE RISE IN INCIDENCE OF CANCER 75
8.1.2 THE FUNDING BY THE GOVERNMENT AND INVESTMENT IN RESEARCH AND DEVELOPMENT 76
8.1.3 RISE IN PIPELINE OR CLINICAL TRIALS OF TAXANE TREATMENTS 76
8.1.4 USE OF REIMBURSEMENT FOR TAXANE 77
8.2 RESTRAINTS 77
8.2.1 SIDE EFFECTS OF DRUGS INCURRED WITH THE TAXANE DRUGS 77
8.2.2 ETHICAL ISSUES RELATED TO THE USE OF TAXANE TREATMENT 78
8.2.3 RISE IN PRODUCT RECALLS 78
8.3 OPPORTUNITIES 79
8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS 79
8.3.2 RISE IN HEALTHCARE EXPENDITURE 79
8.4 CHALLENGES 80
8.4.1 THE LACK OF SKILLED PROFESSIONALS REQUIRED FOR TAXANE DRUG TREATMENT 80
8.4.2 STRINGENT GOVERNMENT REGULATIONS ON TAXANE DRUG TREATMENT 80
9 NORTH AMERICA TAXANE MARKET, BY TYPE 82
9.1 OVERVIEW 83
9.2 PACLITAXEL 86
9.2.1 BY TYPE 86
9.2.1.1 SEMI-SYNTHETIC 87
9.2.1.2 NATURAL 87
9.2.2 BY STRENGTH 87
9.2.2.1 100MG 87
9.2.2.2 200MG 87
9.2.2.3 250MG 87
9.2.2.4 30MG 87
9.2.2.5 260MG 87
9.2.2.6 300MG 88
9.3 DOCETAXEL 88
9.3.1 120MG 89
9.3.2 80MG 89
9.3.3 20MG 89
9.3.4 40MG 89
9.3.5 60MG 89
9.4 CABAZITAXEL 89
9.4.1 60MG 90

10 NORTH AMERICA TAXANE MARKET, BY APPLICATION 91
10.1 OVERVIEW 92
10.2 BREAST CANCER 95
10.3 NON-SMALL CELL LUNG CANCER 95
10.4 PANCREATIC CANCER 96
10.5 OVARIAN CANCER 97
10.6 PROSTATE CANCER 97
10.7 OTHERS 98
11 NORTH AMERICA TAXANE MARKET, BY DRUG TYPE 99
11.1 OVERVIEW 100
11.2 GENERICS 103
11.3 BRANDED 104
12 NORTH AMERICA TAXANE MARKET, BY FORMULATION 105
12.1 OVERVIEW 106
12.2 LIPOSOMES 109
12.3 NANOPARTICLES 109
12.4 POLYMERIC MICELLES 110
12.5 OTHERS 111
13 NORTH AMERICA TAXANE MARKET, BY AGE GROUP 112
13.1 OVERVIEW 113
13.2 ADULT 116
13.2.1 FEMALE 117
13.2.2 MALE 117
13.3 GERIATRIC 117
13.3.1 FEMALE 118
13.3.2 MALE 118
14 NORTH AMERICA TAXANE MARKET, BY END USER 119
14.1 OVERVIEW 120
14.2 HOSPITALS 123
14.3 AMBULATORY SURGICAL CENTERS 123
14.4 SPECIALTY CLINICS 124
14.5 OTHERS 125

15 NORTH AMERICA TAXANE MARKET, BY DISTRIBUTION CHANNEL 126
15.1 OVERVIEW 127
15.2 RETAIL SALES 130
15.2.1 HOSPITAL PHARMACY 130
15.2.2 RETAIL PHARMACY 131
15.2.3 ONLINE PHARMACY 131
15.3 DIRECT TENDER 131
16 NORTH AMERICA TAXANE MARKET, BY REGION 132
16.1 NORTH AMERICA 133
16.1.1 U.S. 142
16.1.2 CANADA 146
16.1.3 MEXICO 150
17 NORTH AMERICA TAXANE MARKET: COMPANY LANDSCAPE 154
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 154
18 SWOT ANALYSIS 155
19 COMPANY PROFILE 156
19.1 BRISTOL-MYERS SQUIBB COMPANY 156
19.1.1 COMPANY SNAPSHOT 156
19.1.2 REVENUE ANALYSIS 156
19.1.3 COMPANY SHARE ANALYSIS 157
19.1.4 PRODUCT PORTFOLIO 157
19.1.5 RECENT DEVELOPMENTS 157
19.2 SANOFI-AVENTIS U.S. LLC 159
19.2.1 COMPANY SNAPSHOT 159
19.2.2 REVENUE ANALYSIS 159
19.2.3 COMPANY SHARE ANALYSIS 160
19.2.4 PRODUCT PORTFOLIO 160
19.2.5 RECENT DEVELOPMENTS 160
19.3 VIATRIS INC. 162
19.3.1 COMPANY SNAPSHOT 162
19.3.2 REVENUE ANALYSIS 162
19.3.3 COMPANY SHARE ANALYSIS 163
19.3.4 PRODUCT PORTFOLIO 163
19.3.5 RECENT DEVELOPMENT 163

19.4 SANDOZ INTERNATIONAL GMBH (A NOVARTIS DIVISION) 164
19.4.1 COMPANY SNAPSHOT 164
19.4.2 REVENUE ANALYSIS 164
19.4.3 COMPANY SHARE ANALYSIS 165
19.4.4 PRODUCT PORTFOLIO 165
19.4.5 RECENT DEVELOPMENTS 166
19.5 FRESENIUS KABI AG (SUBSIDIARY OF FRESENIUS SE & CO. KGAA ) 167
19.5.1 COMPANY SNAPSHOT 167
19.5.2 REVENUE ANALYSIS 167
19.5.3 COMPANY SHARE ANALYSIS 168
19.5.4 PRODUCT PORTFOLIO 168
19.5.5 RECENT DEVELOPMENTS 168
19.6 HIKMA PHARMACEUTICALS PLC 170
19.6.1 COMPANY SNAPSHOT 170
19.6.2 REVENUE ANALYSIS 170
19.6.3 PRODUCT PORTFOLIO 171
19.6.4 RECENT DEVELOPMENTS 171
19.7 ACCORD HEALTHCARE 172
19.7.1 COMPANY SNAPSHOT 172
19.7.2 PRODUCT PORTFOLIO 172
19.7.3 RECENT DEVELOPMENTS 172
19.8 AQVIDA GMBH 173
19.8.1 COMPANY SNAPSHOT 173
19.8.2 PRODUCT PORTFOLIO 173
19.8.3 RECENT DEVELOPMENTS 173
19.9 AUREATE HEALTHCARE 174
19.9.1 COMPANY SNAPSHOT 174
19.9.2 PRODUCT PORTFOLIO 174
19.9.3 RECENT DEVELOPMENTS 174
19.10 CIPLA INC. 175
19.10.1 COMPANY SNAPSHOT 175
19.10.2 REVENUE ANALYSIS 175
19.10.3 PRODUCT PORTFOLIO 176
19.10.4 RECENT DEVELOPMENTS 176
19.11 DR. REDDY’S LABORATORIES LTD. 177
19.11.1 COMPANY SNAPSHOT 177
19.11.2 REVENUE ANALYSIS 177
19.11.3 PRODUCT PORTFOLIO 178
19.11.4 RECENT DEVELOPMENTS 178

19.12 ELEVAR THERAPEUTICS 179
19.12.1 COMPANY SNAPSHOT 179
19.12.2 PRODUCT PORTFOLIO 179
19.12.3 RECENT DEVELOPMENTS 179
19.13 HETERO HEALTHCARE LIMITED. 181
19.13.1 COMPANY SNAPSHOT 181
19.13.2 PRODUCT PORTFOLIO 181
19.13.3 RECENT DEVELOPMENTS 181
19.14 HUIANG PHARMACEUTICAL CO LTD 182
19.14.1 COMPANY SNAPSHOT 182
19.14.2 PRODUCT PORTFOLIO 182
19.14.3 RECENT DEVELOPMENTS 182
19.15 INGENUS PHARMACEUTICALS, LLC 183
19.15.1 COMPANY SNAPSHOT 183
19.15.2 PRODUCT PORTFOLIO 183
19.15.3 RECENT DEVELOPMENTS 183
19.16 LUYE PHARMA GROUP 184
19.16.1 COMPANY SNAPSHOT 184
19.16.2 REVENUE ANALYSIS 184
19.16.3 PRODUCT PORTFOLIO 185
19.16.4 RECENT DEVELOPMENTS 185
19.17 PANACEA BIOTEC 186
19.17.1 COMPANY SNAPSHOT 186
19.17.2 REVENUE ANALYSIS 186
19.17.3 PRODUCT PORTFOLIO 187
19.17.4 RECENT DEVELOPMENTS 187
19.18 PFIZER INC. 188
19.18.1 COMPANY SNAPSHOT 188
19.18.2 REVENUE ANALYSIS 188
19.18.3 PRODUCT PORTFOLIO 189
19.18.4 RECENT DEVELOPMENTS 189
19.19 RPG LIFE SCIENCES LIMITED 190
19.19.1 COMPANY SNAPSHOT 190
19.19.2 REVENUE ANALYSIS 190
19.19.3 PRODUCT PORTFOLIO 191
19.19.4 RECENT DEVELOPMENTS 191
19.20 SAMARTH LIFE SCIENCES PVT. LTD. 192
19.20.1 COMPANY SNAPSHOT 192
19.20.2 PRODUCT PORTFOLIO 192
19.20.3 RECENT DEVELOPMENTS 192
19.21 SAMYANG HOLDINGS CORPORATION. 193
19.21.1 COMPANY SNAPSHOT 193
19.21.2 REVENUE ANALYSIS 193
19.21.3 PRODUCT PORTFOLIO 194
19.21.4 RECENT DEVELOPMENTS 194
19.22 SHENZHEN MAIN LUCK PHAR MACEUTICALS INC. 195
19.22.1 COMPANY SNAPSHOT 195
19.22.2 PRODUCT PORTFOLIO 195
19.22.3 RECENT DEVELOPMENTS 195
19.23 TORRENT PHARMACEUTICALS LTD 196
19.23.1 COMPANY SNAPSHOT 196
19.23.2 REVENUE ANALYSIS 196
19.23.3 PRODUCT PORTFOLIO 197
19.23.4 RECENT DEVELOPMENTS 197
19.24 TAXANE HEALTHCARE 198
19.24.1 COMPANY SNAPSHOT 198
19.24.2 PRODUCT PORTFOLIO 198
19.24.3 RECENT DEVELOPMENTS 198
20 QUESTIONNAIRE 199
21 RELATED REPORTS 202